These results indicate that VTD’s ability to inhibit tumor growth is primarily mediated via the UBXN2A-tumor suppressor axis, whose activation is associated with the suppression of multi-tumorigenic pathways in CRC (10, 12, 14). Here, UBXN2A is linked to colorectal carcinoma.